Clinical Trials Logo

Brain Diseases clinical trials

View clinical trials related to Brain Diseases.

Filter by:

NCT ID: NCT03152188 Completed - Cirrhosis, Liver Clinical Trials

Oral Fecal Transplant in Cirrhosis

Start date: June 12, 2017
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of oral fecal transplant in patients with cirrhosis and hepatic encephalopathy

NCT ID: NCT03138876 Completed - Encephalopathy Clinical Trials

EEG Cap for Identification of Non-Convulsive Status Epilepticus

Start date: May 30, 2017
Phase: N/A
Study type: Interventional

Altered mental status (AMS) is one of the most common reasons for inpatient neurology consultation. Non-convulsive status epilepticus (NCSE) is frequently on the differential diagnosis of the patient with AMS. NCSE becomes more refractory to treatment after one hour of seizure activity, making rapid identification and treatment of NCSE of great clinical importance. Currently, an electroencephalogram (EEG) technologist must be called in from home during non-workday hours in order to obtain a stat EEG. The investigators propose the time required for diagnosis of NCSE at Mayo Clinic can be significantly decreased with rapid placement of an EEG cap by the onsite neurology residents.

NCT ID: NCT03129620 Completed - Hypothermia Clinical Trials

Pharmacokinetics of Ampicillin in Neonates With Moderate to Severe Hypoxic-Ischemic Encephalopathy

Start date: March 2013
Phase: N/A
Study type: Observational

Controlled Hypothermia has become the standard of care for neonates with moderate to severe HIE. Ampicillin and aminoglycosides are drugs that are universally used for the treatment of suspected neonatal sepsis, which may or may not be responsible for the etiology of HIE. Currently, medication dosage regimens are not altered in the setting of CH. A better understanding of the effects of our interventions on this unique population may help us tailor our therapy to the specific circumstances of the patient

NCT ID: NCT03122808 Completed - Clinical trials for Neonatal Encephalopathy

Uterine Activity in Moderate-Severe Neonatal Encephalopathy: A Case Control Study

Start date: September 1, 2016
Phase:
Study type: Observational

Excessive uterine activity may be one of several aetiological factors that contribute to depressed neurological function in the newborn. During labour, uterine contractions can compress the fetal cranium at pressures high enough to impair cerebral perfusion. Contraction rates greater than 7 in 15 minutes are associated with an increased risk of neonatal encephalopathy. The American Congress of Obstetricians and Gynecologists defines uterine tachysystole as more than 5 contractions in 10 minutes, averaged over a 30-minute window. By this definition, excessive uterine activity is common and, at best, a non-specific predictor of depressed neurological function in the newborn. There is a need for predictors of neonatal encephalopathy that are more specific and clinically applicable. Contraction and relaxation duration are two measures that closely reflect the proposed role of excessive uterine activity in the pathogenesis of neonatal encephalopathy. Prolonged contractions with short relaxation periods result in progressive reductions in fetal cerebral oxygenation. Shorter uterine contraction periods are associated with an increased risk of low umbilical cord potential of hydrogen (pH) values. Our primary aim is to measure parameters of uterine activity, for example relaxation and contraction duration, and determine their relationship with the risk of neonatal encephalopathy. We will also investigate how measures of uterine activity interact with other measures of labour and fetal well-being, including cervical dilation rates and fetal heart rate patterns. In babies with neonatal encephalopathy, we will investigate the relationship of uterine activity with electrophysiological, radiological and developmental outcomes. We will perform a retrospective case-control study of babies born in the Rotunda hospital from 2005 until the present. The assessor of the Cardiotocograph (CTG) recordings will be blind to the disease status of the infants. For each recording, every uterine contraction and rest interval will be measured. Summary variables created from these measures will be used to compare the case and control groups. The primary variable will be mean rest interval duration.

NCT ID: NCT03079284 Completed - Clinical trials for Hypoxic-Ischemic Encephalopathy

Holding, Stress, and Bonding During Therapeutic Hypothermia

Start date: March 20, 2017
Phase: N/A
Study type: Interventional

Ten infants undergoing therapeutic hypothermia for hypoxic-ischemic encephalopathy will be enrolled in a new protocol that will allow mothers to hold their infants during the hypothermia treatment period. This is a safety study that will assess whether or not there is an increase in adverse event frequency in infants that are held during hypothermia. Parents and NICU nurses will be given a questionnaire after holding is complete investigating their feelings on maternal-infant bonding and safety of the holding protocol.

NCT ID: NCT03079167 Completed - Clinical trials for Hypoxic-Ischemic Encephalopathy

PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns

PAEAN
Start date: May 14, 2016
Phase: Phase 3
Study type: Interventional

Double-blind, placebo controlled Phase III trial of erythropoietin for hypoxic ischaemic encephalopathy in infants receiving hypothermia. The study aim is to determine whether Epo in conjunction with hypothermia in infants with moderate/severe hypoxic ischaemic encephalopathy (HIE) will improve neurodevelopmental outcomes at 2 years of age, without significant adverse effects, when compared to hypothermia alone.

NCT ID: NCT03077217 Completed - Clinical trials for Covert Hepatic Encephalopathy

Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy

Start date: May 1, 2017
Phase: Phase 4
Study type: Interventional

Several studies have been showed that rifaximin can improve cognitive functions, driving simulator performance and health-related quality of life in patients with minimal hepatic encephalopathy. The aim of this prospective randomized open controlled study was to evaluate the efficacy and safety of rifaximin at different doses for the treatment of covert hepatic encephalopathy.

NCT ID: NCT03071861 Completed - Clinical trials for Neonatal Encephalopathy

Mild Encephalopathy in the Newborn Treated With Darbepoetin

MEND
Start date: December 1, 2017
Phase: Phase 2
Study type: Interventional

This is a Phase II multicenter placebo-controlled randomized, feasibility/safety trial. Infants >34 week gestational age with perinatal acidemia and mild neonatal encephalopathy on the modified Sarnat neurologic examination at less than six hours of age. Participants will be randomized to receive either one dose of Darbepoetin, or placebo within 24 hours of birth. Neurodevelopmental testing (Bayley (III or IV) and Gross Motor Function Assessment) will be performed at 24 months of age. Pharmacokinetics will be assessed on those infants that received Darbe.

NCT ID: NCT03071783 Completed - Clinical trials for Hypoxic Ischemic Encephalopathy

Intra-operative Feed Back on Traction Force During Vacuum Extraction: Safe Vacuum Extraction Alliance

SVEA
Start date: April 1, 2016
Phase: N/A
Study type: Interventional

The objective of the clinical investigation is to test whether intra-operative traction force feed back during vacuum extraction leads to a significant decrease in incidence of brain damage in neonates. By randomization, half of the vacuum extraction patients will be assigned to delivery using a new intelligent handle for vacuum extractions, and half will be assigned to conventional method without traction force measurement.

NCT ID: NCT03065192 Completed - Parkinson's Disease Clinical Trials

Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

Start date: May 11, 2017
Phase: Phase 1
Study type: Interventional

Safety and efficacy of AADC gene transfer in participants with Parkinson's disease.